ADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARES

Addex Therapeutics issued 93,000,000 new registered shares with a nominal value of CHF 0.01 each, fully subscribed by Addex Pharma S.A., its wholly owned subsidiary. The announcement gives no proceeds, purpose, or market reaction.

Analysis

This is not evidence of an external capital raise: the subscriber is wholly owned, so any subscription cash transfer is eliminated on consolidation. The issuance could improve liquidity at the parent-company level only if the subsidiary contributes cash or other value, but the announcement does not disclose the consideration or its source. The key market question is therefore the legal and economic treatment of the subsidiary-held shares—not the nominal amount alone. Verify the subscription price, pro forma share count, voting and dividend rights, and whether the shares are treated as treasury shares under the applicable rules. If they are later transferred to outside investors, they could create dilution or a tradable overhang; if retained or cancelled, the public-float impact may be limited. Near term, the signal is weak absent evidence of new external financing or a change in clinical funding runway. Over 1–3 months, filings clarifying share treatment and use of proceeds are the relevant catalysts. Over 6–18 months, financing needs and clinical progress are more consequential to valuation than this intra-group transaction. A thesis of meaningful dilution is falsified if filings show no increase in externally held shares and no change in voting or economic rights; it strengthens if the shares become transferable or Addex revises funding plans.

Key Decisions for Investors

• No trade on this announcement alone; avoid treating the stated share issuance as an external equity financing or assuming the nominal value is the subscription proceeds.
• Put ADXN on a filing watchlist for the subscription price, pro forma share count, subsidiary-held-share treatment, and any subsequent transfer, cancellation, or resale.
• Reassess only if the shares enter public hands or the company provides evidence that the transaction materially changes parent-level liquidity or the clinical funding runway.
• Falsify a dilution-overhang thesis if subsequent disclosures confirm the shares remain non-voting/non-economic treasury-type holdings and public float is unchanged; escalate concern if they become freely transferable.